Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 3-4/2017

01.03.2017 | main topic

Pyoderma gangrenosum—a novel approach?

verfasst von: Dr. Anastasia Atanasova Chokoeva, MD José Carlos Cardoso, Prof. Dr. Uwe Wollina, Assoc. Prof. Georgi Tchernev

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Pyoderma gangrenosum (PG) represents a rare skin disorder, with several clinical variants and still not fully understood ethiopathogenesis. Often associated with inflammatory or neoplastic disease, PG is nowadays considered an inflammatory neutrophilic disease with common underlying morbidity. Modern treatment options are oriented towards key mechanisms underlying the pathogenesis of the disease, namely inflammatory mediators, and seem to be the most effective treatment currently available. Although promising, the results are not invariable and these treatments are sometimes surrounded by controversy, as recent studies have reported cases that are refractory to therapy with biological agents. It is possible that refractoriness to the use of biological agents as monotherapy stems from the fact that a single agent is not able to affect the entire inflammatory cascade, or to simultaneously influence all of its levels. Based on the pathogenesis of inflammation, we can suggest that an ideal targeted therapy should be able to induce the following changes: 1) reduction of the secretion of interleukin (IL)-1a/b from the inflammasome with subsequent blocking of its biological effect (by therapy with IL-1 receptor antagonists); 2) blocking of the activation of the secreted procytokines in their active form (by therapy with caspase-1 inhibitors; 3) blocking of the effect of the already released active cytokines (by therapy with tumour necrosis factor alpha, TNF-α, inhibitors); 4) blocking of the effector action of the cytokines on the target intracellular molecules (by therapy with kinase inhibitors). The specific therapy should aim to attack more than one link in the inflammatory cascade, in order to achieve maximum therapeutic effectiveness. Most surely, this could be achieved with combined therapy with different groups of biological agents (for example a combined therapy with IL-1 receptor antagonist and a TNF-α inhibitor). Currently, no data in the literature exist to support this statement, and there are no safety data relating to such approaches. We focus this review on the novel etiopathogenetic concepts of PG and the future therapeutic approaches based on blocking different levels of the inflammatory cascade, which seems to be the most promising weapon in the target-oriented treatment options.
Literatur
1.
Zurück zum Zitat Cozzani E, Gasparini G, Parodi A. Pyoderma gangrenosum: a systematic review. G Ital Dermatol Venereol. 2014;149(5):587–600. PubMed Cozzani E, Gasparini G, Parodi A. Pyoderma gangrenosum: a systematic review. G Ital Dermatol Venereol. 2014;149(5):587–600. PubMed
2.
Zurück zum Zitat Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164:263. CrossRefPubMed Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164:263. CrossRefPubMed
3.
Zurück zum Zitat Gameiro А, Pereira N, Cardoso JC, Margarida Gonçalo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:285–93. CrossRefPubMedPubMedCentral Gameiro А, Pereira N, Cardoso JC, Margarida Gonçalo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:285–93. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-Sánchez M, Hernández-Durán M, Castro-Senosiain B, Fernández-Villaverde A, García-Sánchez V, Domínguez-Muñoz E, Caunedo-Álvarez A, Herrerías-Gutiérrez JM. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949–54. CrossRefPubMed Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-Sánchez M, Hernández-Durán M, Castro-Senosiain B, Fernández-Villaverde A, García-Sánchez V, Domínguez-Muñoz E, Caunedo-Álvarez A, Herrerías-Gutiérrez JM. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949–54. CrossRefPubMed
5.
Zurück zum Zitat Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014;134(7):1805–10. CrossRefPubMed Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014;134(7):1805–10. CrossRefPubMed
6.
Zurück zum Zitat Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–58. CrossRefPubMed Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149–58. CrossRefPubMed
7.
Zurück zum Zitat Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139(6–7):459–67. CrossRefPubMed Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139(6–7):459–67. CrossRefPubMed
8.
Zurück zum Zitat Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka TJ. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. Am Acad Dermatol. 2012;66(3):409–15. CrossRef Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka TJ. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. Am Acad Dermatol. 2012;66(3):409–15. CrossRef
9.
Zurück zum Zitat Charles A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. CrossRef Charles A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. CrossRef
11.
Zurück zum Zitat Dinarello CA, Meer JW van der. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;pii: S1044-5323(13):00089–00084. Dinarello CA, Meer JW van der. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;pii: S1044-5323(13):00089–00084.
13.
Zurück zum Zitat Jaeger T, Andres C, Grosber M, Zirbs M, Hein R, Ring J, Traidl-Hoffmann C. Pyoderma gangrenosum and concomitant hidradenitis suppurativa – rapid response to canakinumab (anti-IL-1b). Eur J Dermatol. 2013;23(3):408–10. PubMed Jaeger T, Andres C, Grosber M, Zirbs M, Hein R, Ring J, Traidl-Hoffmann C. Pyoderma gangrenosum and concomitant hidradenitis suppurativa – rapid response to canakinumab (anti-IL-1b). Eur J Dermatol. 2013;23(3):408–10. PubMed
14.
Zurück zum Zitat Church LD, Cook GP. Michael F McDermott. Primer: inflammasomes and interleukin 1 bold beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42. CrossRefPubMed Church LD, Cook GP. Michael F McDermott. Primer: inflammasomes and interleukin 1 bold beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42. CrossRefPubMed
15.
Zurück zum Zitat Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002;65:16–21. PubMed Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002;65:16–21. PubMed
16.
Zurück zum Zitat Dinarello CA, Simon A, Meer JWM van der. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–52. CrossRefPubMedPubMedCentral Dinarello CA, Simon A, Meer JWM van der. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–52. CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter E, Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest. 2000;80(4):595–604. CrossRefPubMed Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter E, Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest. 2000;80(4):595–604. CrossRefPubMed
18.
Zurück zum Zitat Rallis E, Koumantaki-Mathioudaki E, Tsiatoura A, Stavropoulos P, Katsambas A. Pyoderma gangrenosum and tumor necrosis factor α agents. Cutis. 2013;92(4):E1–2. PubMed Rallis E, Koumantaki-Mathioudaki E, Tsiatoura A, Stavropoulos P, Katsambas A. Pyoderma gangrenosum and tumor necrosis factor α agents. Cutis. 2013;92(4):E1–2. PubMed
19.
Zurück zum Zitat Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ. 2007;14:73–8. CrossRefPubMed Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ. 2007;14:73–8. CrossRefPubMed
20.
Zurück zum Zitat Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1(2):74–8. CrossRefPubMedPubMedCentral Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1(2):74–8. CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261–5. CrossRefPubMed Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261–5. CrossRefPubMed
22.
Zurück zum Zitat Tchernev G, Trebing D, Göring H‑D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn’s disease – the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56–60. Tchernev G, Trebing D, Göring H‑D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn’s disease – the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56–60.
23.
Zurück zum Zitat Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930–3. PubMed Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930–3. PubMed
24.
Zurück zum Zitat Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis. 2014;8(1):85–6. CrossRefPubMed Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J Crohns Colitis. 2014;8(1):85–6. CrossRefPubMed
25.
Zurück zum Zitat Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg. 2005;9(6):296–302. CrossRefPubMed Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg. 2005;9(6):296–302. CrossRefPubMed
26.
Zurück zum Zitat Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm. 2013;2013:939847. CrossRef Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm. 2013;2013:939847. CrossRef
27.
Zurück zum Zitat Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14. CrossRefPubMed Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14. CrossRefPubMed
28.
Zurück zum Zitat Chen TL, Chang CC, Lin YL, Ueng YF, Chen RM. Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 beta gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells. Toxicol Appl Pharmacol. 2009;240(1):15–25. CrossRefPubMed Chen TL, Chang CC, Lin YL, Ueng YF, Chen RM. Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 beta gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells. Toxicol Appl Pharmacol. 2009;240(1):15–25. CrossRefPubMed
29.
Zurück zum Zitat Wu GJ, Chen TL, Ueng YF, Chen RM. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4‑mediated c‑Jun N‑terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol. 2008;228(1):105–13. CrossRefPubMed Wu GJ, Chen TL, Ueng YF, Chen RM. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4‑mediated c‑Jun N‑terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol. 2008;228(1):105–13. CrossRefPubMed
30.
Zurück zum Zitat Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7(4):271–5. CrossRefPubMed Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7(4):271–5. CrossRefPubMed
31.
Zurück zum Zitat Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161(5):1199–201. CrossRefPubMed Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161(5):1199–201. CrossRefPubMed
32.
Zurück zum Zitat Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, Ponweiser E, Eckhart L, Sunder-Plassmann R. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209–15. CrossRefPubMed Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, Ponweiser E, Eckhart L, Sunder-Plassmann R. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209–15. CrossRefPubMed
34.
Zurück zum Zitat Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2012;18(8):413–5. CrossRefPubMed Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2012;18(8):413–5. CrossRefPubMed
35.
37.
Zurück zum Zitat Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol. 1996;34:395–409. CrossRefPubMed Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol. 1996;34:395–409. CrossRefPubMed
38.
Zurück zum Zitat Goodarzi H, Sivamani RK, Garcia MS, Wehrli LN, Craven H, Ono Y, Maverakis E. Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle). 2012;1(5):194–9. CrossRef Goodarzi H, Sivamani RK, Garcia MS, Wehrli LN, Craven H, Ono Y, Maverakis E. Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle). 2012;1(5):194–9. CrossRef
Metadaten
Titel
Pyoderma gangrenosum—a novel approach?
verfasst von
Dr. Anastasia Atanasova Chokoeva
MD José Carlos Cardoso
Prof. Dr. Uwe Wollina
Assoc. Prof. Georgi Tchernev
Publikationsdatum
01.03.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2017
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0472-z